BACKGROUND

- Multiple myeloma is the second most prevalent hematological malignancy, with a treatment cost of €11,000–18,000 per patient per year.
- Most patients with multiple myeloma are elderly (median age 63 years), which makes them especially vulnerable to treatment-related complications.

OBJECTIVES

- To determine the total costs of treatment for patients with symptomatic multiple myeloma in the UK.
- To assess the impact of different treatment regimens on clinical outcomes.

METHODS

- A retrospective chart review study using retrospective data from the University Hospitals of Leicester NHS Trust.
- Data on patient characteristics, level of response to treatment, costs and healthcare utilization (HRU) were collected.
- Included treatment regimens were: lenalidomide, bortezomib, pomalidomide, and bendamustine.

RESULTS

- **Table 1:** Descriptive patient demographics and disease characteristics for all patients.

- **Table 2:** Mean duration of treatment for all patients, by treatment period and level of response.

- **Table 3:** Mean (standard deviation) total and monthly costs (€) of treatment for all patients, by treatment period and level of response.

- **Table 4:** Distribution of costs (excluding cost of anti-tumor treatments) and management of AEs for all patients, by treatment period.

LIMITATIONS

- The results of this study are limited by the use of retrospective data.
- The study was conducted in a single center, which may limit its generalizability.

CONCLUSIONS

- The costs of treatment for patients with symptomatic multiple myeloma in the UK vary significantly depending on the treatment regimen.
- The highest costs were associated with lenalidomide-containing regimens, followed by bortezomib and pomalidomide.

ACKNOWLEDGMENTS

- The authors would like to thank the patients who participated in the study and the healthcare professionals who provided data.
- Financial support was provided by the University Hospitals of Leicester NHS Trust.

REFERENCES

- Name et al. (2016). Multiple myeloma in the UK: Incidence, treatment, and outcomes. Leukemia & Lymphoma.

FIGURES

- Figure 1: Treatment periods identified within a line of therapy.
- Figure 2: Total costs for all patients, by treatment period.
- Figure 3: Mean duration of treatment for all patients, by treatment period and level of response.
- Figure 4: Distribution of costs (excluding cost of anti-tumor treatments) and management of AEs for all patients, by treatment period.